In a groundbreaking development poised to reshape antiviral therapeutic strategies, researchers Liu, Bai, Zhou, and colleagues have unveiled a novel benzothiazole-based allosteric inhibitor that targets the human angiotensin-converting enzyme 2 (ACE2) receptor, demonstrating potent activity across the pan-sarbecovirus subgenus. Published in the prestigious journal Nature Communications in 2026, this study opens new avenues in the fight against current and future coronavirus pandemics by exploiting a highly conserved viral entry mechanism through a uniquely human protein interface.
The ACE2 receptor has been firmly established as the primary gateway for several sarbecoviruses, including the infamous SARS-CoV and SARS-CoV-2, facilitating viral entry into host cells. This receptor-binding interface has remained a prime target for antiviral interventions aimed at halting infection at the earliest stages. However, direct viral protein-targeted therapies often suffer from rapid viral mutation rates and escape variants, rendering many antiviral drugs less effective over time. The current study circumvents this hurdle by focusing on an allosteric inhibition mechanism directed at the host receptor itself rather than the viral proteins.
Central to the researchers’ approach is the design and synthesis of a benzothiazole scaffold capable of binding selectively to ACE2 at an allosteric site distinct from the virus-binding domain. This strategy effectively modulates the conformation of ACE2, thereby diminishing its affinity for the spike protein of pan-sarbecoviruses. By altering the receptor landscape, the inhibitor prevents viral attachment and fusion without directly engaging viral antigens, substantially reducing the risk of resistance development.
The team employed an integrated suite of computational modeling, structural biology, and biochemical assays to identify and optimize the benzothiazole moiety as an allosteric ligand. High-throughput virtual screening was initially utilized to survey vast chemical spaces, targeting pocket regions on ACE2 predicted to influence spike binding indirectly. Subsequent crystallographic analyses confirmed the binding mode and shed light on critical interaction networks stabilizing the inhibitor-receptor complex.
Functional validation involved rigorous in vitro analyses using pseudovirus and live virus systems representing diverse sarbecoviruses. The benzothiazole-based inhibitor demonstrated robust antiviral efficacy with low micromolar IC50 values across multiple viral strains, including emerging variants posing current global health threats. Importantly, cytotoxicity assays revealed minimal off-target effects on host cell viability, underscoring the compound’s favorable therapeutic index.
Mechanistic exploration pointed to allosteric perturbation of ACE2’s receptor-binding domain orientation, which in turn impairs spike protein recognition. This modulation, unlike orthosteric inhibitors, preserves ACE2’s physiological enzymatic functions, a crucial consideration given ACE2’s role in cardiovascular homeostasis. The ability to selectively interfere with viral attachment while sparing endogenous enzymatic activity marks a significant advancement in host-targeted antiviral design.
Extending their findings to in vivo models, the researchers observed pronounced protection against viral challenge in murine models expressing human ACE2, with treated animals exhibiting markedly reduced viral loads and ameliorated lung pathology. Pharmacokinetic profiling indicated favorable absorption, distribution, metabolism, and excretion (ADME) properties for the benzothiazole inhibitor, supporting its candidacy for further preclinical and clinical development.
The implications of this research are far-reaching, especially considering the zoonotic potential of sarbecoviruses and the inevitability of future spillover events. Conventional antiviral drug pipelines often struggle to keep pace with viral evolution, yet targeting a conserved host factor like ACE2 through allosteric mechanisms may offer a resilient and broad-spectrum solution. Such host-directed therapies could complement existing vaccines and antiviral agents, providing a multi-layered defense against pandemics.
Moreover, the innovative application of allostery expands the toolkit available to medicinal chemists working on infectious diseases. By shifting focus from direct viral blockade to modulation of host-virus interaction interfaces, this study underscores the value of detailed structural understanding combined with chemical ingenuity. The benzothiazole framework, due to its modularity and synthetic accessibility, promises a versatile platform that could be further optimized or derivatized for enhanced potency and specificity.
As the global scientific community grapples with both ongoing and emerging infectious threats, the lessons from this study highlight the importance of interdisciplinary approaches that combine virology, structural biology, and chemistry. The convergence of computational and experimental methodologies allowed the researchers to navigate the complex landscape of host receptor pharmacology, achieving breakthrough results that might have been elusive through traditional trial-and-error screening.
Looking forward, the translation of this benzothiazole-based allosteric inhibitor into clinical use will require extensive safety and efficacy trials. Potential interactions with the renin-angiotensin system and long-term effects of ACE2 modulation will need careful evaluation. Nonetheless, the prospect of a pan-sarbecovirus therapeutic that can be rapidly deployed in response to future outbreaks offers hope for better pandemic preparedness.
This report from Liu and colleagues exemplifies the innovative spirit driving modern antiviral research. By shifting paradigms away from virus-centric drug design towards strategic manipulation of host-virus interfaces, it sets a new standard for how medical science can preemptively disarm a broad spectrum of dangerous pathogens before they escalate into global crises.
As the study sees further dissemination and inspires follow-up investigations, the benzothiazole allosteric inhibitor may well establish a new class of antiviral agents that are not only effective but also strategically durable against viral evolution. Its development signals a critical step towards liberation from the reactive cycles of epidemic response, ushering in a more proactive and anticipatory era of infectious disease management.
The excitement surrounding this breakthrough is palpable within the scientific community, as many experts recognize the potential for this inhibitor to act as a foundational molecule upon which future antiviral therapies are built. This approach honors the complexity of viral-host interactions, acknowledging that sometimes the most effective intervention resides not in attacking the invader directly, but in smartly defending the host.
In sum, the research presented heralds a promising new chapter in antiviral therapeutics, leveraging the precision of allosteric modulation to safeguard one of humanity’s critical molecular sentinels—ACE2. By doing so, it not only counters the immediate threats posed by sarbecoviruses but also charts a course for enduring protection against a wider array of related coronaviruses.
Subject of Research: Development of a benzothiazole-based allosteric inhibitor targeting human ACE2 to inhibit pan-sarbecovirus infections.
Article Title: Human angiotensin‑converting enzyme 2‑specific benzothiazole-based allosteric inhibitor against pan‑sarbecoviruses.
Article References: Liu, L., Bai, J., Zhou, R. et al. Human angiotensin‑converting enzyme 2‑specific benzothiazole-based allosteric inhibitor against pan‑sarbecoviruses. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73944-x
Image Credits: AI Generated
